News of Note—VBI Vaccines, BiondVax and more

In this week's news of note, VBI Vaccines won FDA approval to start phase 3 testing on its hep B shot Sci-B-Vac, which is licensed in 15 countries.

> VBI Vaccines won FDA approval for its phase 3 program of hep B shot Sci-B-Vac. Enrollment is expected to start this year in the U.S., Europe and Canada. The vaccine is already licensed in Israel and 14 other countries. Release

> AMAL Therapeutics raised €8 million to advance its experimental colorectal cancer vaccine into human testing. story

> BiondVax, which is working on a universal flu vaccine candidate, voluntarily delisted from the Tel Aviv Stock Exchange. The company is still listed on Nasdaq. Release


Simplify and Accelerate Drug R&D With the MarkLogic Data Hub Service for Pharma R&D

Researchers are often unable to access the information they need. And, even when data does get consolidated, researchers find it difficult to sift through it all and make sense of it in order to confidently draw the right conclusions and share the right results. Discover how to quickly and easily find, synthesize, and share information—accelerating and improving R&D.

Suggested Articles

In an effort to stop an Ebola outbreak that has claimed 2,200 lives at the Rwanda border, J&J is shipping 200,000 doses of its vaccine to the country.

Merck just last month won the world's first licensure for an Ebola vaccine. Now, an international group authorized funding to establish a stockpile.

GSK expects Shingrix supplies to rise slightly in 2020, but the real "step change" will come in 2024 with a brand-new manufacturing facility.